Skip to main content
  • Saved

Commented on 's Post

Amgen Announces Five-Year Data That Reinforce The Safety And Efficacy Profile Of Aimovig (erenumab-aooe) In Adult Patients With Episodic Migraine

Amgen Announces Five-Year Data That Reinforce The Safety And Efficacy Profile Of Aimovig (erenumab-aooe) In Adult Patients With Episodic Migraine

Source :

https://pharmashots.com/press-releases/amgen-announces-five-year-data-that-reinforce-the-safety-and-efficacy-profile-of-aimovig-erenumab-aooe-in-adult-patients-with-episodic-migraine/

Results Presented at the Migraine Trust Virtual Symposium Highlight Long-Term Benefit of Aimovig Aimovig Has the Longest Duration of Safety and Efficacy Trial Data for Any Anti-CGRP Pathway Therapy Five-Year Open-label Extension Study Shows Patients Continued to Experience a Sustained Benefit; Aimovig Maintained a Consistent Safety Profile THOUSAND OAKS, Calif., Oct.